Bio-Rad Laboratories BIO Clinical Diagnostics — Goodwill
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:GoodwillGross.
The official record: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Rad Laboratories's clinical diagnostics — goodwill.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Rad Laboratories's clinical diagnostics — goodwill?
- Bio-Rad Laboratories (BIO) reported clinical diagnostics — goodwill of $421.8M in Q1 2026.
- How has Bio-Rad Laboratories's clinical diagnostics — goodwill changed year-over-year?
- Bio-Rad Laboratories's clinical diagnostics — goodwill increased by 1.3% year-over-year, from $416.5M to $421.8M.
- What is the long-term trend for Bio-Rad Laboratories's clinical diagnostics — goodwill?
- Over 4 years (2021 to 2025), Bio-Rad Laboratories's clinical diagnostics — goodwill has grown at a 4.7% compound annual growth rate (CAGR), from $1.4B to $1.68B.
- What does clinical diagnostics — goodwill mean?
- Represents the total carrying value of goodwill specifically allocated to the Clinical Diagnostics business segment. This asset arises when the purchase price of an acquired business in this segment exceeds the fair value of its identifiable net assets.